Breast Cancer Stages, Clearly Explained by a Specialist
Breast cancer staging goes beyond a number. Your biomarker profile, TNM substage, and NCI SEER 2026 survival data shape your actual prognosis.
Sameer Patel — Founder & Editor
Sameer Patel is the founder and editor of My Medicine Advisor. He is not a doctor or medical professional — before starting this site he worked in banking, and he now researches and edits health information full-time.
He started My Medicine Advisor to make clear, well-sourced health information freely available to anyone. Every article is researched from recognised authorities such as the WHO, CDC, NIH, and NICE, drafted with the help of AI tools, and edited by hand, with sources linked so readers can check them. The calculators on the site use established, published formulas, each one named so you can look it up yourself.
My Medicine Advisor is currently a one-person operation with no clinical review panel, and the site is open about that. If you're a qualified clinician or researcher interested in reviewing content, Sameer would genuinely like to hear from you via the contact page.
Recognizing Breast Cancer Symptoms Before They Progress
Breast cancer symptoms — most of them painless — have a 99% 5-year survival rate when localized. Here's what an oncologist checks first.
Breast Cancer Stages and Survival: What You Need to Know First
Breast cancer stage guides treatment—but receptor subtype changes the plan. An oncologist explains all four treatment pathways using NCCN 2026.
Trusted Palliative Care Guide for Lung Cancer Patients
Palliative care for lung cancer isn't hospice — NCCN 2026 recommends concurrent enrollment from diagnosis. An oncologist explains when to start.
Liquid Biopsy for Lung Cancer: The Clear Clinical Answer on ctDNA
Liquid biopsy detects EGFR and T790M mutations from a blood draw—no surgery. A board-certified oncologist explains when NCCN 2026 endorses it over tissue biopsy.
Your Lung Cancer Genetic Test Results, Made Clear
Lung cancer genetic testing covers 9 biomarker targets per 2026 NCCN — each linked to an FDA-approved drug. Know what your EGFR, ALK, or KRAS G12C result means.
Your Clear Path Through Lung Cancer Clinical Trial Enrollment
Clinical trial patients in Phase III receive standard care—not placebo. Lung cancer eligibility: ECOG 0–2, biomarker profile, 4 enrollment steps inside.
Radiation Therapy for Lung Cancer: What the 2026 Data Shows
SBRT delivers 93% 1-year local control for lung cancer in 1–5 sessions. Compare SBRT vs. IMRT vs. surgery with 2026 data — and know which side effects require same-day action.
Lung Cancer Prognosis: A Clear Stage-by-Stage Guide
Lung cancer prognosis ranges from 63% at Stage I to 7% at Stage IV — biomarkers like EGFR can transform those numbers. See what your oncologist assesses.
Lung Cancer Metastasis: 5 Real Sites, Symptoms and Options
Lung cancer metastasis: In EGFR-mutant NSCLC, brain involvement is common — and osimertinib's CNS penetration makes it the preferred choice.